We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
PGEN's shares surged 52.5% in three months, fueled by Papzimeos and pipeline progress.
Papzimeos generated $74.6 million in six-month 2026 sales, with Q2 revenues more than doubling sequentially.
PGEN awaits European review while advancing PRGN-2009 and its broader AdenoVerse pipeline.
Shares of Precigen (PGEN - Free Report) have witnessed a sharp increase in the past three months, driven by growing investor optimism surrounding the strong commercial performance of the company’s sole marketed drug, Papzimeos (zopapogene imadenovec-drba), as well as broader pipeline progress.
Papzimeos is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The product has demonstrated strong early commercial momentum since its approval and launch in 2025.
In the first six months of 2026, Papzimeos generated $74.6 million in revenues. Importantly, product revenues from Papzimeos sales more than doubled sequentially during the second quarter of 2026.
Precigen is also pursuing additional growth opportunities outside the United States. A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe.
A potential approval in Europe could further boost the drug’s sales and drive revenues.
PGEN’s Price Performance
Shares of Precigen have surged 52.5% in the past three months against the industry’s decline of 0.2%.
Image Source: Zacks Investment Research
More on PGEN’s Papzimeos & Other Pipeline
The approval of Papzimeos transitioned Precigen from a development-stage to a commercial-stage company.
The sustained commercial momentum could support revenue growth for Precigen through the remainder of 2026. Sales are expected to grow steadily as Precigen expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Papzimeos.
Meanwhile, Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals (INO - Free Report) is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application seeking approval for INO-3107 in RRP is currently under review in the United States. A decision from the FDA is expected on Oct. 30, 2026.
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in HPV-driven cancers. The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform.
A multicenter phase II study is evaluating PRGN-2009 in combination with Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in patients with recurrent or metastatic cervical cancer.
Merck’s biggest revenue driver, Keytruda, is approved for several types of cancers globally.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
The company's recent developments and continued momentum in Papzimeos sales, along with encouraging pipeline progress, should continue the upward momentum for PGEN stock for the rest of 2026.
View the Zacks #1 Rank List
Image: Bigstock
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Key Takeaways
Shares of Precigen (PGEN - Free Report) have witnessed a sharp increase in the past three months, driven by growing investor optimism surrounding the strong commercial performance of the company’s sole marketed drug, Papzimeos (zopapogene imadenovec-drba), as well as broader pipeline progress.
Papzimeos is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The product has demonstrated strong early commercial momentum since its approval and launch in 2025.
In the first six months of 2026, Papzimeos generated $74.6 million in revenues. Importantly, product revenues from Papzimeos sales more than doubled sequentially during the second quarter of 2026.
Precigen is also pursuing additional growth opportunities outside the United States. A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe.
A potential approval in Europe could further boost the drug’s sales and drive revenues.
PGEN’s Price Performance
Shares of Precigen have surged 52.5% in the past three months against the industry’s decline of 0.2%.
Image Source: Zacks Investment Research
More on PGEN’s Papzimeos & Other Pipeline
The approval of Papzimeos transitioned Precigen from a development-stage to a commercial-stage company.
The sustained commercial momentum could support revenue growth for Precigen through the remainder of 2026. Sales are expected to grow steadily as Precigen expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Papzimeos.
Meanwhile, Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals (INO - Free Report) is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application seeking approval for INO-3107 in RRP is currently under review in the United States. A decision from the FDA is expected on Oct. 30, 2026.
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in HPV-driven cancers. The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform.
A multicenter phase II study is evaluating PRGN-2009 in combination with Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in patients with recurrent or metastatic cervical cancer.
Merck’s biggest revenue driver, Keytruda, is approved for several types of cancers globally.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
The company's recent developments and continued momentum in Papzimeos sales, along with encouraging pipeline progress, should continue the upward momentum for PGEN stock for the rest of 2026.
Precigen, Inc. Price
Precigen, Inc. price | Precigen, Inc. Quote
PGEN’s Zacks Rank
Precigen currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.